• Leukemias, lymphomas, and other hematologic cancers

Cytarabine Generic Name & Formulations

General Description

Cytarabine 100mg, 500mg, 1g, 2g; per vial; lyophilized pwd for IV, intrathecal, SC inj after reconstitution.

Pharmacological Class


How Supplied

Vials (100mg, 200mg)—10
1g, 2g—1

Cytarabine Indications


Remission induction in acute non-lymphocytic leukemia of adults and children. Acute lymphocytic leukemia. Chronic myelocytic leukemia (blast phase). Prophylaxis and treatment of meningeal leukemia (intrathecal route).

Cytarabine Dosage and Administration

Adults and Children

Induction therapy of acute non-lymphocytic leukemia: 100mg/m2 per day by continuous IV infusion (days 1–7) or 100mg/m2 IV every 12 hours (days 1–7). Acute lymphocytic leukemia and chronic myelocytic leukemia: see literature. Meningeal leukemia: Usual range: 5–75mg/m2 intrathecally; may give once daily for 4 days to once every 4 days; most frequently used dose: 30mg/m2 every 4 days until cerebrospinal fluid findings are normal.

Cytarabine Contraindications

Not Applicable

Cytarabine Boxed Warnings

Not Applicable

Cytarabine Warnings/Precautions


Do not use diluent with benzyl alcohol for intrathecal administration. Pre-existing myelosuppression. Renal or hepatic impairment. Monitor blood counts, renal, hepatic function. Neonates. Pregnancy (Cat.D); avoid use. Nursing mothers.

Cytarabine Pharmacokinetics

See Literature

Cytarabine Interactions


May antagonize gentamicin, fluorocytosine.

Cytarabine Adverse Reactions

Adverse Reactions

Myelosuppression (leukopenia, thrombocytopenia, anemia), GI upset, anorexia, abdominal pain, oral ulceration, rash, fever, hepatic dysfunction, infection, bleeding; cytarabine syndrome, hyperuricemia, pancreatitis, paralysis (rare), others.

Cytarabine Clinical Trials

See Literature

Cytarabine Note

Not Applicable

Cytarabine Patient Counseling

See Literature